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Abstract
The majority of the human genome comprises of DNA genes that are translated into RNAs but not into 
proteins. These RNA molecules are named non-coding RNAs (ncRNA). While in the past it was thought 
that ncRNAs would be redundant without relevant functions, it is now well established that ncRNAs 
identify a class of regulatory molecules that finely tune cell homeostasis and are deregulated in disease 
states, including Hepatocellular Carcinoma (HCC). Of note, the number of ncRNAs within a cell increases 
progressively with the complexity of the species indicating their essential role in the maintenance of 
regulatory networks that impact the intricacy of the organism. ncRNAs have been demonstrated to mediate 
HCC development and progression by affecting intrinsic cancer cell signaling and cross talk between 
malignant cells and the microenvironment. They hold promise as clinical biomarkers, but further evidence 
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Introduction
Over recent years considerable progress has been made in characterizing the molecular alterations 
underlying the development of HCC(1). Numerous post-transcriptional RNA modifications regulating 
multiple gene expression processes have been discovered as a result of advances in molecular biology and 
detection methodologies. While most modifications occur in the “classical” mRNA and tRNA, several 
classes of functional RNA that possess no or low coding potential have been identified(2,3). Less than 2% 
of the genome encodes for proteins but three-quarters are transcribed in non-coding RNAs (ncRNA) 
suggesting the existence of an intricate RNA-based network with regulatory functions. NcRNA has been 
divided in different classes according to molecular size: 1) small RNAs are usually 20–30 nucleotides long 
being classified into 3 major types in animals: microRNA (miRNA), siRNA and PIWI-interacting RNA 
(piRNA), 2) long non-coding RNAs (lncRNAs) being > 200 nucleotides.  
MicroRNAs
MiRNAs represent the dominant class of small RNAs, regulating protein-coding genes through 
translational repression and mRNA degradation(4). Regulation of miRNAs occurs at multiple levels of 
miRNA biogenesis. Genomic sequences for miRNAs genes are transcribed to primary miRNAs by RNA 
polymerase II in the nucleus under the positive or negative regulation of transcription factors and epigenetic 
mechanisms. Pri-miRNAs are then processed by the nuclear RNase III Drosha and by the cytoplasmatic 
Rnase III Dicer to generate a miRNA complex with two strands. While one strand is depredated, the other 
is bound onto AGO protein to form an effector complex called RNA-induced silencing complex(RISC)(4). 
While the majority of evidence suggests that miRNAs bind to the 3’ UnTranslated Region (3’-UTR), 
crosslinking and immunoprecipitation experiments have recently shown that translational inhibition can 
also occur through the binding of miRNA within the coding region and 5’-UTR(5). MiRNA deregulation 
happens through several mechanisms in HCC, including chromosomal alterations, promoter methylation 
and aberrant expression of transcription factors. Recently,  mutation of DICER1 has been identified in 
2.3% of sporadic HCC, that are characterized by a decreased expression of mature miRNAs compared to 
wild type tumors(6). Taken together, these findings suggest that alterations in the miRNA-processing 
machinery could potentially influence HCC development(7), underlining an important regulatory role of 
ncRNAs for the fine-tuning of cell homeostasis. 
MiRNAs and HCC Initiation
The aberrant expression of ncRNAs has been observed at different stages of liver disease and ultimately in 
HCC. MiR-122 is the most abundant miRNA in the liver, accounting for more than 70% of the hepatocyte 
miRNome. Integral to various metabolic functions including fatty-acid metabolism(8), cell differentiation 
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inflammation-mediated hepatocarcinogenesis, as miR-122 deficient mice develop steatohepatitis, fibrosis 
and spontaneous liver tumors(9). Different clusters of miRNAs have been identified in association with 
different etiologies, as pathways involved in regulation of immune response, cell cycle and metabolisms are 
activated by hepatite C  virus (HCV)-associated miRNAs, whereas pathways regulating cell death, DNA 
damage and signal transduction are preferentially activated during hepatite B virus (HBV) infection. 
However, common miRNAs are necessary for the progression from chronic infection to HCC, independent 
from the predisposing condition(10). Biopsies from patients with Non-Alcoholic Heapatosteatosis (NASH) 
also showed a specific pattern of 23 deregulated miRNAs(11). Specific miRNAaccording to the different 
pathogens therefore deliver a synergistic action through impacting on multiple self-sustaining cellular 
processes, leading to a global impairment of the cellular networks that ultimately drive malignant 
transformation. The mechiansms by which chronic inflammation, HBV, HCV and NAFLD promote cancer 
initiation through miRNAs deregulation are detailed in the supplementary materials.
MiRNAs and HCC Progression
Even though miRNA impairment is an early event in hepatocarcinogenesis, there is evidence for a 
sequential global miRNA downregulation occurring in the progression from early to metastatic 
tumors(12)[Figure 1].  For example, miR-122 downregulation promotes the activation of miRNAs/mRNAs 
usually expressed in embryonic liver and drives a more aggressive phenotype associated with poor clinical 
outcome(13). Using a mathematical modelling approach, Gerard et al showed how miRNAs interact with 
protein partners to generate a regulatory network that sustains HCC progression(14) and that includes Let-
7b, CTNNB1, LIN28B, SOX9, P53 and MYC. The deregulation of this gene regulatory network was 
associated with HCCs characterized by poor differentiation and prognosis. Such evidence suggest that, as 
miRNA impairment is an early event in hepatocarcinogenesis, there is a sequential global miRNA 
downregulation from normal liver tissue to HCC and subsequently during metastases.
Growing evidence is supporting an important role for miRNAs to regulate the cross-talk between cancer 
cells and microenvironment. MiR-210 is known to respond to hypoxic stress in cancer;  in HCC, miR-210 
sustains HCC growth in hypoxic conditions via regulation of the vacuole-membrane-protein (VMP)1 and 
the tissue inhibitor of metalloproteinases (TIMP)2(15,16). Re-organization of the matrixome is also 
mediated by miR-29b that can downregulate matrix-metaloproteinases (MMP)2, while having also an 
effect on epithelial cell apoptosis(17). miR-148a affects fibrosis and regulates the plasticity of hepatocytes, 
while miR-125b and miR-100 promote venous invasion which favors recurrence and metastatisation in 
HCC(18,19). The onset of distant metastases is a late event in HCC and is nurtured by the transition of 
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miR-101 remodel the cytoskeleton by acting on the Rho/RoCK signaling, which results in an increased 
ability of HCC cells to migrate and invade(20–22). EMT is then sustained by paracrine signaling 
originating from other microenvironment components including cancer-associate-fibroblasts (CAF). Recent 
work shows that CAFs are recruited in the metastatic niche by the release of miR-1247-containing 
exosomes from HCC cells(23). In turn, CAFs create a vicious loop by releasing miRNAs (i.e. miR-335), 
sustaining HCC cell proliferation(24). 
MiRNAs are also known to govern the interplay between cancer cells and immune cells. For example, loss 
of miR-34 can promote immune-escape by altering the profile of cytokines that recruit and activate T-
regulatory cells (Treg)(25). Cytokines are also central to a miRNA-mediated negative feedback loop that 
occurs between HCC cells and tumour associated macrophages (TAM). Lack of miR28-5-p in HCC leads 
to increased interleukin-34 that recruits TAMs, which in turn inhibit miR28-5 via TGF-B and IL-6; the 
latter recognized as a promoter of HCC progression through its action on the HCC stem-cells niche(26). 
Stemness features are then nourished by the crosstalk with tumor-associated neutrophils (TANs) and is 
mediated by the effect of TAN-derived miR301-3p on HCC cells(27). 
miRNAs as clinical molecular biomarkers
Novel diagnostic tools are required to detect HCC at an early stage as well as serve as prognostic and 
predictive biomarkers to enhance clinical decision-making [Figure 2]. 
MiRNAs actively contribute to the development of HCC, and aberrant miRNA expression patterns 
distinguish HCC from adjacent normal and cirrhotic tissues(28,29). MiRNAs can be released into the 
circulation 1) passively as free RNAs due to cell death, 2) associated to lipoproteins and RNA binding 
proteins, or 3) secreted into extracellular vesicles(30). In all cases, circulating miRNAs are present in the 
circulation in a highly stable form protected from RNAses. Several single circulating miRNAs have been 
suggested as diagnostic biomarkers, yet to date have demonstrated limited diagnostic accuracy. 
Combinations of multiple miRNAs have been demonstrated to increase specificity and diagnostic accuracy 
for HCC; however, most studies are limited by small sample size and lack of independent validation. 
Among those studies that identified, and independently validated, panels of miRNA with diagnostic 
potential, Li et al. evaluated 13 miRNAs associated with HCC identifying miR-25, miR-375, and let-7f to 
clearly segregate HCC cases from healthy controls (AUC=99.9)(31). Zhou et al. profiled miRNAs 
expression in 934 patients and identified a dysregulated miRNA panel composed of miR-122, miR-192, 
miR-21, miR-223, miR-26a, miR-27a and miR-801, capable of differentiating HCC from healthy controls 
(AUC = 0.941), chronic hepatitis B (AUC = 0.842), and cirrhosis (AUC = 0.884), independent of HCC 
stage(32). However, miR-1228 expression was used as a stable endogenous control for normalization, 
while it is known to promote HCC and being present at higher levels in the plasma of patients with Budd-
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Lin et al. recently studied a cohort of 1416 Chinese patients with liver diseases, including a nested case-
control cohort. They identified a panel of 7 miRNAs (miR-29a, miR-29c, miR-133a, miR-143, miR-145, 
miR-192, and miR-505), which distinguished patients with HCC from individuals with chronic hepatitis B, 
HBV-induced liver cirrhosis, and healthy controls(34). While promising, further validation is warranted 
before this panel can be considered for clinical application. As this study comprised mainly of HBV-
positive patients, how these data can be translated to HCC secondary to other etiologies requires 
investigation, given that at least tissue miRNA expression is dependent on the causative factor. Overall, 
studies of circulating miRNAs as diagnostic biomarkers have not shown high reproducibility, and this may 
be related, at least partly, to the modulation of circulating miRNAs induced by several pathological 
conditions including inflammation, sepsis, cardiological and immunological disease. It is likely that their 
value will be better served within multiplex-assays where miRNA deregulation is paired to other 
components, such as circulating tumor DNA that enhances specificity. 
Neoplastic progression with the development of distant metastases is the primary cause of the high 
mortality of patients with HCC. Reduced miR-26 tissue expression was shown to be a significant 
prognostic marker in a large cohort of clinically annotated HCC tissues; it associates with a transcriptomic 
inflammatory signature exhibiting negative prognostic value after curative surgery, but positive predictive 
value for response to adjuvant interferon(35). Based on these findings, a prospective clinical trial was 
launched to inform adjuvant treatment (with Interferon) according to miR-26 expression levels 
(NCT01681446), with results presently awaited. Various authors have analyzed miRNA expression and 
associated clinical data from large publicly available HCC datasets, including the TCGA and NCBI Gene 
Expression Omnibus(36,37), observing various prognostic miRNA signatures. Variability likely reflects the 
vast heterogeneity among HCC patients in terms of the pathogenic factors and etiologies involved. Tumor 
progression is known to rely not solely on intrinsic epithelial features, but on the interaction with several 
cell types that contribute to a favorable soil for tumor growth; given miRNAs play a key role in tuning the 
crosstalk with the microenvironment, it is likely that they represent promising factors to assess patients’ 
prognosis. However, in order to overcome lack of reproducibility amongst studies, large cohorts are 
required within the framework of prospective randomized trials.
MicroRNAs have been shown to affect key survival and cell death signaling pathways, determining the 
cellular stress response induced by drug treatment(38). It is now known that drug response in patients is 
mediated by a plethora of factors extending beyond tumor to include network signaling within the 
microenvironment and the host immune response. In addition, patients’ comorbidities represent a key 
factor that impacts fitness, drug metabolism and tolerability, as well as drug response. Thus, the capacity of 
circulating miRNAs to reflect the overall homeostasis of the organism provides an additional level of 
complexity with potential to enhance prediction of drug response (especially to non-targeted therapies) and 









This article is protected by copyright. All rights reserved
robust transcriptomic subgroups, each characterized by a peculiar differentiation state and by different 
miRNA profiles. However, when response to different therapeutic agents was evaluated, miRNA 
expression showed a lower predictive ability than mRNA expression(39), likely reflecting a lack of detail 
regarding microenvironment and cell-to-cell interaction in this model. 
Currently, therapeutic options for advanced HCC include multikinase-inhibitors such as sorafenib and 
regorafenib. Fornari et al identified circulating miR-221 as a mediator of sorafenib resistance in vitro and in 
vivo, which was confirmed in small retrospective cohorts of HCC patients(40) while serum miR-181a-5p 
was recently found to be independently associated with disease control following therapy(41). While 
prospective validation is required in larger cohorts, these findings highlight how an integrated approach 
involving interrogation of biological processes and translational analyses hold promise for the identification 
of predictive biomarkers. The introduction of novel technologies, such as quantitative digital PCR, may 
define a cut-off value for miRNA expression that can be used prospectively by enabling counting of 
circulating RNA molecules per volume of fluid. It is expected that the introduction of these technologies 
within ancillary translational analyses of prospective randomized clinical trials will help to clarify the 
predictive role of miRNAs in HCC. Such an example is provided by the translational study within the 
RESORCE trial, which provided evidence for regorafenib treatment in HCC patients(42).Teufel et al 
reported the clinical value of a set of miRNAs (miR-15b, miR-107, miR-320b, miR-122, miR-374b, miR-
200a, miR-30a, miR-125b, miR-645) in identifying survival benefit from regorafenib(43). Given the nature 
of the trial (prospective, randomized, with treatment and control arm), these findings represent the most 
robust data to support the clinical utility of miRNAs to date(43). However, in order to progress 
prospectively, a quantitative assessment of RNA molecules is necessary to identify a robust threshold 
applicable on a patient-per-patient basis. Given that the greatest challenge currently faced in HCC treatment 
is the identification of patients who derive a long-term benefit from check point inhibitors(44,45), it would 
be interesting to investigate the role of ncRNAs in predicting immunotherapy response. While no data exist 
for HCC, a combination of circulating miRNAs and PD-L1 expression defines a niche of lung cancer 
patients who benefit from immunotherapy(46). Similarly, a panel of aberrant miRNAs was recently shown 
to be involved in the development of resistance to immunotherapy in melanoma patients(47). Additional 
evidence suggest that ncRNAs may drive lymphocyte differentiation and that non-coding regions represent 
the major source of targetable tumor-specific antigens(48,49). Taken together, these findings suggest that 
aberrantly expressed ncRNA might have a critical role in driving tumor immunogenicity and may 
potentially serve as predictors of immunotherapy response in HCC. 
Long non-coding RNAs 
LncRNAs comprise various RNA species ranging from 200nt to ~100kb in length. They function as ligands 
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Expression of lncRNAs is more tissue specific than miRNAs, and distinct expression patterns exist across 
different stages of tissue differentiation, indicating different regulatory roles in diverse cellular 
contexts(50). Nuclear lncRNAs promote transcriptional modulation of targeted genes by recruiting and 
guiding chromatin modifiers to specific genomic loci. Among these, the polycomb-group-complex 2 
(PRC2) is frequently recruited by lncRNAs in HCC mediating gene silencing by establishing a repressive 
chromatin status. Cytoplasmatic lncRNAs appear to modulate mRNA stability and regulate translational 
and post-translational modifications, by directly targeting mRNA or by acting as “endogenous competing 
RNA” that compete with protein-coding genes for for the binding site of regulatory miRNAs, resulting in 
decreased miRNA activity and detection(51). 
LncRNAs and carcinogenesis
Depending on HCC etiology, different lncRNAs have been demonstrated to contribute to HCC initiation. In 
HBV-related HCC, the lncRNA HOTAIR is overexpressed and interacts with the PCR2 complex to control 
chromatin remodeling. Different mechanisms have been postulated to explain the interactions between 
HOTAIR and the PCR2 subunits, which are mediated by either protein complexes (i.e. SUZ12 and EZH2) 
or RNAs (i.e.miR-218)(52). 
The oncogenic lncRNA HEIH interacts with EZH2 to deregulate the PRC2 complex and promote 
epigenetic silencing of tumor suppressor genes(53). HBx can induce aberrant expression of lncRNAs with 
oncogenic function, such as DBH-AS1 and UCA1. DBH-AS1 promotes HCC cell proliferation and tumor 
growth by suppressing p53 and activating MAPK signaling, while UCA1 suppresses p27 through histone 
methylation on its promoter(54). In addition, UCA1 reduces expression of the tumor suppressor miR-
216b(55). The HBV genome can integrate into host DNA to form a hybrid lncRNA transcript called HBx-
LINE1, detectable in 23% of HBV associated HCC, it functions as a molecular sponge binding and 
sequestering miR-122(56,57). Finally, Hbx can downregulate lncRNAs with tumor suppressive function, 
such as Dreh, which combines with and alters the structure of the mesenchymal protein vimentin(58). 
Profiling data on human HCC identified Linc01419 in early stage disease, and AK021443 and AF070632 
as lncRNA specific for advanced stage HCC(59).
LncRNAs prognostic role and cancer progression
The lncRNA DANCR is over-expressed in cells with stemness features and is clinically associated with 
HCC recurrence and poor prognosis. Functional analyses revealed that DANCR promotes metastatic 
progression by associating with CTNNB1 mRNA thereby blocking the repressing effect that miR-214, 
miR-320a, and miR-199a have on CTNNB1(60). The lncRNA UFC1 interacts with the RNA binding 
protein HuR preventing -catenin degradation and increasing cytoplasmatic levels(61). The ultraconserved 
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transformation, providing the basis for using this lncRNA as biomarker for the targeted use of wnt 
inhibitors(62). Expression of the lncRNA Highly Up-regulated in Liver Cancer (HULC), is associated with 
intrahepatic metastases, HCC recurrence, and shorter postoperative survival, promoting progression 
through numerous oncogenic mechanisms. HULC acts as a scaffold for the phosphorylation of YB-1 that 
accelerates the translation of oncogenic mRNAs, as cyclin D1, cyclin E1, and MMP11(63). In addition, 
HULC targets MiR-200a-3p resulting in an increased expression of EMT markers(64), it promotes 
neoangiogenesis by targeting the tumor angiogenesis-associated factors SPHK1(65) and contributes to the 
abnormal lipid metabolism of hepatoma cells(66). Both lncRNAs Zeb1-AS1 and ZFAS1 are frequently 
overexpressed in HCC and are clinically associated with the development of metastases and reduced 
recurrence free survival. They promote neoplastic progression by interacting with the transcription factor 
ZEB1, a direct repressor of E-cadherin(67,68). ZFAS1 promotes the development of intrahepatic and 
extrahepatic metastasis by binding miR-150 and abrogating its tumor-suppressive function on ZEB1 and 
the matrix metalloproteinases(68). 
There is evidence that LncRNAs are differently expressed in neoplastic vein thrombus, compared to the 
matching primary, with ICAM-1-related (ICR) and the lncRNA-activated by TGF-b (lncRNA-ATB) both 
highly expressed in neoplastic thrombus, and correlated with metastases development and shorter 
survival(69). ATB promotes EMT and invasion by competitive binding and inactivating members of the 
miR-200 family, promoting survival of the metastatic cells by increasing the stability of IL11 mRNA and 
activation of STAT3 signaling at metastatic sites(70). High expression of the LncRNA MVIH is associated 
with microvascular invasion and is an independent risk factor for recurrence following HCC resection(71). 
Among lncRNAs with tumor suppressive function, CPS1-IT1 and AOC4P showed reduced expression in 
up to 70% of HCC samples potentially affecting prognosis through EMT suppression(72,73). The 
integrated analysis of copy number variations and lncRNAs on resected specimens identified the recurrent 
deletion of PRAL (p53 regulation-associated lncRNA) to be associated with poor survival in HCC patients. 
PRAL enhanced p53 stability by facilitating the combination of HSP90 and p53 and therefore 
competitively inhibiting the p53 negative regulator Mdm2(74).
CircRNA in HCC
Circular RNA (circRNA) recently emerged as a widespread and abundant class of RNA transcripts that 
play an active role in gene regulation. CircRNA are generated by back-splicing of pre-RNA with the 3′ and 
5′ ends that are covalently closed in a continuous loop. They can contain exons, introns or intergene non-
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proteins to regulate gene expression. Altered circRNAs have been described in HCC suggesting a role in its 
development and progression.
A noncoding network driven by the circRNA CircCDYL was recently found to be specifically upregulated 
in very early stage HCCs. CircCDYL inhibits miR-892a and miR-328-3p expression and activates the 
PI3K-AKT- mTORC1/β-catenin and NOTCH2 pathways, increasing the proportion of stem-like cells 
within the tumor(75). By using circRNA seq, circASAP1was found overexpressed in resected HCC tissue 
and plasma of patients experiencing ecurrence in the lungs and poor prognosis. CircASAP1 acts by 
sponging tumor suppressive miR-326 and miR-532-5p, which results into MAPK signaling activation and 
increased TAM infiltration(76). 
Circular RNA MAT2B (circMAT2B) has a role in reprogramming cancer metabolism by increasing 
glycolysis under tumoral hypoxia. CircMAT2B upregulates PKM2 activity, a key enzyme in the glycolysis 
process, by sponging miR-338-3p and blocking PKM2 degradation(77).
Among dowregulated circRNAs, CircMTO1 targets the oncogenic miR-9, thus inhibiting p21 and being 
associated with shortened survival(78). Although RNA and the protein encoded by SMARCA5 are usually 
upregulated in HCC, suggesting its potential role as tumor promoter, its circular product, cSMARCA5, is 
downregulated due to the increased activity of the nuclear RNA helicase DHX9.  cSMARCA5 promotes 
expression of the tumor suppressor TIMP3 by sponging miR-17-3p and miR-181b-5p and its 
downregulation is associated with  aggressive clinicopathological characteristics and poor prognosis(79).
Future perspectives: targeting ncRNAs for HCC treatment
Targeting ncRNAs represent a promising therapeutic strategy by pursuing inhibition or replacement of 
miRNAs, splicing regulation via intronic RNAs, and establishment of long ncRNA-based therapeutics to 
target repetitive RNA and modulation of gene expression. However, despite success of  preclinical models, 
their clinical application remains in its infancy. 
The systemic administration of miR-26a in HCC mouse model, using adeno-associated virus as a platform 
for miRNA delivery, resulted in the inhibition of cancer cell proliferation and reduction of tumor size and 
nodules(80). Similarly, the systemic delivery of miR-101 in HCC mouse models, using a lentivirus-based 
vector, resulted in inhibition of tumor angiogenesis and cancer cell invasiveness, suppressing intrahepatic 
and distant metastases. Both studies did not report significant toxicity in animals(81). However, the 
delivery of miRNA mimics remain more challenging in humans, with the risk of RNA degradation and 
inactivation via blood stream. To overcome this issue encapsulation of miRNA in nanovescicles carriers 
has been recently pursued with success in terms of deliverability. However, two issues are still to be 
resolved: 1) tissue specificity for delivery to the target-organ, and 2) side effects from the carriers. While 
delivery to liver is somewhat less challenging than other organs due to the liver double circulation, the 
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Liposomal IV injection of miRRX34, (Mirna Therapeutics), in patients with advanced or metastatic cancer, 
including unresectable HCC, was evaluated in a phase I clinical trials. However, the trial was terminated 
due to immune related serious adverse events observed in five patients(82). Consistent with these findings, 
a phase I trial investigating miRNA replacement in mesothelioma patients confirmed a severe 
immunological toxicity mediated by nanoparticles, suggesting that better delivery strategies for miRNAs 
are necessary for human studies. Another limitation of the replacement strategy stems from the introduction 
of supra-physiological levels of miRNAs, beyond that usually present within cells, inducing over-saturation 
of the targets and high toxicity. Subsequently, greater attention has been given to inhibitory strategies 
where the aberrant expression of a given non-coding RNA is counteracted by inhibitory molecules that 
eliminate the disproportional level without introducing external unphysiological active molecules. Clinical 
trials in cancers and other diseases are ongoing with Locked Nucleic Acid miRNA inhibitors, which seem 
to be feasible and less toxic. However, results have to be awaited before proving their efficacy.
Conclusions
Although recent studies have provided great insights into the importance of ncRNA in enhancing HCC 
initiation and progression, there remains much to be elucidated. Functional analyses integrated with clinical 
data have exposed a complex regulatory network in which several classes of ncRNAs interact via a 
complex network to regulate cell homeostasis and promote malignant phenotypes. NcRNAs primarily exert 
regulatory role that drives different phenotypes by controlling several intracellular pathways, 
communication between cancer cells, as well as other cell types in the microenvironment. Therefore, it is 
likely that a combination of several models that depict intracellular epithelial features (2D cell lines), cell-
to-cell interaction (3D cancer models), cross-talk between different cell types (co-cultures) and host 
components including the immune response (in vivo models) are necessary to elucidate the regulatory role 
of ncRNAs in HCC. Association of pre-clinical investigations with large-scale studies embedded within 
clinical trials may provide the translational evidence to identify clinically relevant and reproducible non-
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Figure 1. Biological role of miRNAs in HCC initiation and progression: MiRNAs have an active role in 
hepatocarcinogenesis depending on the different pathogenic factors and etiologies involved. MiRNAs 
promote HCC initiation by enhancing persistent inflammation and by deregulating signaling pathways that 
control cell cycle and apoptosis. MiRNAs contribute to HCC progression by  promoting epithelial to 
mesenchymal transition (EMT), matrix reorganization and neoangiogenesis and by impairing 
immunogenicity within tumor microenvironment via the interactions between cancer cells and 
immune/inflammatory cells, such as cancer associated fibroblasts (CAF), regulatory T cells (regTcells), 
tumor associate macrophages (TAM) and tumor associate neutrophils (TAN). 
Figure 2. Clinical roles of ncRNAs: Diagnostic: combinations of circulating miRNAs have been 
proposed to enhance diagnostic accuracy for HCC. Prognostic: Several aberrantly expressed ncRNA in 
resected specimens have a key role in the development of metastases and can potentially serve as 
prognostic biomarkers. Predictive: In patients with advanced HCC, circulating miRNAs are associated 
with the development of drug resistance and disease control in course of Sorafenib. By analysing patients 
included in the RESORCE trial, a set of miRNAs identify survival benefits in course of Regorafenib. 
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